Premium
Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation
Author(s) -
KIENAST J.,
JUERS M.,
WIEDERMANN C. J.,
HOFFMANN J. N.,
OSTERMANN H.,
STRAUSS R.,
KEINECKE HO.,
WARREN B. L.,
OPAL S. M.
Publication year - 2006
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2005.01697.x
Subject(s) - medicine , disseminated intravascular coagulation , concomitant , sepsis , antithrombin , placebo , complication , heparin , drotrecogin alfa , thrombosis , surgery , gastroenterology , septic shock , severe sepsis , pathology , alternative medicine
Summary. Background: Disseminated intravascular coagulation (DIC) is a serious complication of sepsis that is associated with a high mortality. Objectives: Using the adapted International Society on Thrombosis and Haemostasis (ISTH) diagnostic scoring algorithm for DIC, we evaluated the treatment effects of high‐dose antithrombin (AT) in patients with severe sepsis with or without DIC. Patients and Methods: From the phase III clinical trial in severe sepsis (KyberSept), 563 patients were identified (placebo, 277; AT, 286) who did not receive concomitant heparin and had sufficient data for DIC determination. Results: At baseline, 40.7% of patients (229 of 563) had DIC. DIC in the placebo‐treated patients was associated with an excess risk of mortality (28‐day mortality: 40.0% vs. 22.2%, P < 0.01). AT‐treated patients with DIC had an absolute reduction in 28‐day mortality of 14.6% compared with placebo ( P = 0.02) whereas in patients without DIC no effect on 28‐day mortality was seen (0.1% reduction in mortality; P = 1.0). Bleeding complications in AT‐treated patients with and without DIC were higher compared with placebo (major bleeding rates: 7.0% vs. 5.2% for patients with DIC, P = 0.6; 9.8% vs. 3.1% for patients without DIC, P = 0.02). Conclusions: High‐dose AT without concomitant heparin in septic patients with DIC may result in a significant mortality reduction. The adapted ISTH DIC score may identify patients with severe sepsis who potentially benefit from high‐dose AT treatment.